How to appeal a Highmark iv iron infusion denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for iv iron infusion

Cited policy: BCBS Iron Therapy in HFrEF — IV Ferric Carboxymaltose

HFrEF / HFmrEF with iron deficiency (ferritin <100 OR 100-299 with TSAT <20%) to improve symptoms and reduce HF hospitalizations.

How Highmark denies iv iron infusion — and how to counter it

Where Highmark pushes back: 1) Ferritin >100 — not iron deficient; 2) Try oral iron first.

Counter-arguments that hold up: ESC 2021 HF Guidelines (McDonagh Eur Heart J 2021;42:3599) — Class IIa for IV FCM in HFrEF iron def. Ferritin <100 OR 100-299 + TSAT <20% IS iron deficient in HF context. FAIR-HF NEJM 2009 + CONFIRM-HF Eur Heart J 2015 + AFFIRM-AHF Lancet 2020 + HEART-FID NEJM 2023. Oral iron does NOT improve HFrEF outcomes (IRONOUT-HF JAMA 2017 negative).

What Highmark typically denies for iv iron infusion

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For iv iron infusion, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the iv iron infusion treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Injectafer
• Monoferric
• Feraheme
• Venofer
• INFeD
• Triferic (HD)

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.